

NOVARTIS AG

ISIN: CH0012005267

WKN: 1200526

Overview

--	
Price	-
Difference	- (-)

General attributes	
ISIN	CH0012005267
Symbol	NOVN
Exchange	-
Currency	-
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	203,935 EUR
Benchmark	SWISS MARKET INDEX

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	-
High	-
Low	-
Close (prev. day)	-
VWAP	-
Volume (pcs)	-
Trading volume	-
Number of trades	-
Last size	-

Futures and Options	
Related Futures	30
Related Options	-

PDF Downloads	
Company report: NOVARTIS AG	



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

on instrument	on sector	on market	
Date		Headline	Download
2024/09/11		Global Equity Ratings	
2024/09/05		Global Equity Ratings	
2024/08/12		Global Equity Ratings	
2024/07/24		Global Equity Ratings	
2024/07/12		Global Equity Ratings	


Details

--	
Price	-
Difference	- (-)

General attributes	
ISIN	CH0012005267
Symbol	NOVN
Exchange	-
Currency	-
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	203,935 EUR
Benchmark	SWISS MARKET INDEX

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	-
High	-
Low	-
Close (prev. day)	-
VWAP	-
Volume (pcs)	-
Trading volume	-
Number of trades	-
Last size	-

Performance and Risk			
	6m	1Y	3Y
Perf (%)	-	-	-
Perf (abs.)	-	-	-
Beta	-	-	-
Volatility	-	-	-



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	-- (-)
Ø price 30 days Ø volume 30 days (pcs.)	-- (-)
Ø price 100 days Ø volume 100 days (pcs.)	-- (-)
Ø price 250 days Ø volume 250 days (pcs.)	-- (-)
YTD High date	-- (-)
YTD Low date	-- (-)
52 Weeks High date	-- (-)
52 Weeks Low date	-- (-)

Company profile

Company Logo



Contact Details

NOVARTIS AG

--

Lichtstrasse 35 - 4056 Basel

Telefon: +41-61-324-11-11

Fax: +

E-mail: -

PDF Downloads

Company report: NOVARTIS AG



Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Members of Management Board

Vasant (Vas) Narasimhan	Chairman of Managing Board
Klaus Moosmayer	Member of Executive Committee
Steffen Lang	Member of Executive Committee
Aharon Gal	Member of Executive Committee
Fiona H. Marshall	Member of Executive Committee
Harry Kirsch	Member of Executive Committee
Karen Hale	Member of Executive Committee
Kees Rokx	Member of Executive Committee
Lutz Hegemann	Member of Executive Committee
Michelle Weese	Member of Executive Committee
Patrick Horber	Member of Executive Committee
Rob Kowalski	Member of Executive Committee
Shreeram Aradhye	Member of Executive Committee
Victor Bulto	Member of Executive Committee

Board of directors

Charles Sawyers	Member of the administrative board
Nancy Andrews	Member of the administrative board
Simon Moroney	Member of the administrative board
Ana de Pro Gonzalo	Member of the administrative board
Bridgette Heller	Member of the administrative board
Daniel Hochstrasser	Member of the administrative board
Frans van Houten	Member of the administrative board
John Young	Member of the administrative board
Mary Doherty	Member of the administrative board
Patrice Bula	Member of the administrative board
Ton Büchner	Member of the administrative board
William Winters	Member of the administrative board
Hans Jörg Reinhardt	Chairman of the administrative board